The online version of this article (doi:10.1007/s00428-014-1667-6) contains supplementary material, which is available to authorized users.
Gastric cancer is the second most common cause of cancer-related death worldwide, and the incidence of esophageal adenocarcinoma is rising. While some progress has been made in treatment strategies, overall survival remains very poor for patients with adenocarcinoma in the upper gastrointestinal tract. Special AT-rich sequence binding protein 1 (SATB1) is a global genome organizer that has been demonstrated to promote aggressive tumor behavior in several different types of cancer, including gastric cancer. The prognostic value of SATB1 expression in esophageal cancer has, however, not yet been described. In this study, expression of SATB1 was examined by immunohistochemistry on tissue microarrays prepared from tissue samples from 175 patients with adenocarcinoma of the esophagus, cardia, or stomach and containing normal tissue, intestinal metaplasia, primary tumors, and metastases. A well-validated antibody was used. We found SATB1 to be an independent prognostic factor in patients with a radically resected tumor, correlating with shorter overall survival as well as with shorter recurrence-free survival. SATB1 expression was also found to be significantly lower in primary tumors associated with intestinal metaplasia than those without intestinal metaplasia. This observation is of potential biological interest as it has been proposed that intestinal metaplasia-associated tumors constitute a less aggressive phenotype.
ESM 1 (DOCX 95 kb)428_2014_1667_MOESM1_ESM.docx
Lauwers GY (2009) Epithelial neoplasms of the stomach. In:Odze RD, Goldblum JR (eds) Surgical pathology of the GI tract, liver, biliary tract and pancreas, volume 1, 2nd edn. Elsevier, Philadelphia, p 563–580
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697 PubMedCrossRef
Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, Zhan L, Li Y, Zhou ZG, Sun XF (2012) Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Color Dis 27(2):143–150 CrossRef
Al-Sohaily S, Henderson C, Selinger C, Pangon L, Segelov E, Kohonen-Corish M, Warusavitarne J (2013) Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer. Histopathology 65(2):155–63. doi:10.1111/his.12295
Lu X, Cheng C, Zhu S, Yang Y, Zheng L, Wang G, Shu X, Wu K, Liu K, Tong Q (2010) SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep 24(4):981–987 PubMed
Jonsson L, Hedner C, Gaber A, Korkocic D, Nodin B, Uhlen M, Eberhard J, Jirstrom K (2014) High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death. Biomark Res 2:11 PubMedCentralPubMedCrossRef
Demicco EG, Farris AB 3rd, Baba Y, Agbor-Etang B, Bergethon K, Mandal R, Daives D, Fukuoka J, Shimizu M, Dias-Santagata D et al (2011) The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 24(9):1177–1190 PubMedCrossRef
- SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma
- Springer Berlin Heidelberg